← Back to Search

Neuroprotection System

NPS for Ischemic Stroke (NITE1 Trial)

N/A
Waitlist Available
Led By Charles Matouk, MD
Research Sponsored by Silk Road Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

NITE1 Trial Summary

This trial is to see if a new neuroprotection system is safe and feasible to use for people who have had a failed transfemoral endovascular therapy for anterior circulation strokes.

Eligible Conditions
  • Stroke

NITE1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Device-related Serious Adverse Events
Functional independence at 90-days
Other Serious Adverse Events

NITE1 Trial Design

1Treatment groups
Experimental Treatment
Group I: NOVIS Transcarotid Neuroprotection System (NPS)Experimental Treatment1 Intervention
Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.

Find a Location

Who is running the clinical trial?

Silk Road MedicalLead Sponsor
8 Previous Clinical Trials
1,508 Total Patients Enrolled
Charles Matouk, MDPrincipal InvestigatorYale University

Media Library

NOVIS Transcarotid Neuroprotection System (Neuroprotection System) Clinical Trial Eligibility Overview. Trial Name: NCT04881162 — N/A
Stroke Research Study Groups: NOVIS Transcarotid Neuroprotection System (NPS)
Stroke Clinical Trial 2023: NOVIS Transcarotid Neuroprotection System Highlights & Side Effects. Trial Name: NCT04881162 — N/A
NOVIS Transcarotid Neuroprotection System (Neuroprotection System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04881162 — N/A
~9 spots leftby May 2025